 MONT-SAINT-GUIBERT, Belgium, Jan. 18, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced updates from the Phase 1 alloSHRINK trial evaluating CYAD-101, the Companys allogeneic NKG2D-receptor and T cell receptor TCR inhibitory molecule TIM-based, non-gene edited CAR T candidate administered concurrently with FOLFOX chemotherapy for the treatment of refractory metastatic colorectal cancer mCRC, presented at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium ASCO-GI, held virtually from January 15-17, 2021. 